Rocket Pharmaceuticals (RCKT) Amortization of Deferred Charges (2022 - 2026)

Rocket Pharmaceuticals has reported Amortization of Deferred Charges for 4 years, with the latest figure at $151000.0 in Q4 2017.

• Quarterly Amortization of Deferred Charges rose 7.86% year-over-year to $151000.0 in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $581000.0 (down 41.78% YoY) and the FY2017 annual result came in at $581000.0, up 161.71% from the prior year.
• Amortization of Deferred Charges rose to $151000.0 in Q4 2017 per RCKT's latest filing, from $148000.0 in the prior quarter.
• Over five years, Amortization of Deferred Charges peaked at $555000.0 in Q3 2015 and troughed at $59000.0 in Q3 2014.
• A 4-year average of $198500.0 and a median of $145500.0 in 2017 frame the typical range for Amortization of Deferred Charges.
• The sharpest annual moves came in 2015 and 2017: Amortization of Deferred Charges surged 840.68% in 2015, then climbed 7.86% in 2017.
• Over 4 years, Amortization of Deferred Charges stood at $73000.0 in 2014, then surged by 660.27% to $555000.0 in 2015, then plunged by 74.77% to $140000.0 in 2016, then advanced by 7.86% to $151000.0 in 2017.
• According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $151000.0, $148000.0, and $143000.0 for Q4 2017, Q3 2017, and Q2 2017 respectively.